| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.57(B) |
| Last
Volume: |
1,947,382 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,815,444 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
51 |
93 |
| End Date |
2024-03-30 |
2023-12-28 |
2023-06-29 |
2022-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alvarez Ralph |
Director |
– • – |
2018-06-18 |
4 |
A |
$86.11 |
$10,936 |
D/D |
127 |
40,845 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-15 |
4 |
S |
$86.65 |
$15,597,720 |
D/D |
(180,000) |
122,050,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-14 |
4 |
S |
$86.31 |
$9,295,414 |
D/D |
(107,698) |
122,230,804 |
|
- |
|
| Skovronsky Daniel |
SVP, CSO, and Pres. LRL |
• – – |
2018-06-14 |
4 |
B |
$86.22 |
$862,200 |
D/D |
10,000 |
55,199 |
2.74 |
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-13 |
4 |
S |
$86.27 |
$957,953 |
D/D |
(11,104) |
122,338,502 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-11 |
4 |
S |
$86.38 |
$4,422,637 |
D/D |
(51,198) |
122,349,606 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-04 |
4 |
S |
$85.13 |
$11,532,565 |
D/D |
(135,478) |
122,400,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-06-01 |
4 |
S |
$85.31 |
$3,371,661 |
D/D |
(39,522) |
122,536,282 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-05-31 |
4 |
AS |
$85.00 |
$2,125,000 |
D/D |
(25,000) |
124,534 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-05-30 |
4 |
S |
$83.85 |
$15,092,640 |
D/D |
(180,000) |
122,575,804 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2018-05-29 |
4/A |
AS |
$82.10 |
$691,775 |
D/D |
(8,426) |
0 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2018-05-29 |
4 |
S |
$82.10 |
$691,775 |
D/D |
(8,426) |
0 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2018-05-21 |
4 |
A |
$81.83 |
$9,656 |
D/D |
118 |
5,953 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2018-05-21 |
4 |
A |
$81.83 |
$5,483 |
D/D |
67 |
58,843 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2018-05-21 |
4 |
A |
$81.83 |
$10,883 |
D/D |
133 |
40,455 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-05-11 |
4 |
S |
$81.97 |
$11,475,940 |
D/D |
(140,000) |
122,755,804 |
|
- |
|
| Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2018-05-03 |
4 |
AS |
$78.50 |
$708,620 |
D/D |
(9,027) |
135,458 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-05-01 |
4 |
D |
$81.07 |
$724,279 |
D/D |
(8,934) |
149,534 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
158,468 |
|
- |
|
| Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2018-05-01 |
4 |
D |
$81.07 |
$706,606 |
D/D |
(8,716) |
144,485 |
|
- |
|
| Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2018-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
153,201 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2018-05-01 |
4 |
D |
$81.07 |
$431,617 |
D/D |
(5,324) |
8,426 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2018-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,750 |
13,750 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-04-25 |
4 |
S |
$80.85 |
$14,553,614 |
D/D |
(180,000) |
122,895,804 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-04-16 |
4/A |
S |
$80.08 |
$1,391,710 |
D/D |
(17,379) |
40,685 |
|
- |
|
1436 Records found
|
|
Page 35 of 58 |
|
|
7.78 (0.86%) 
